Sort   by:  
 Page size 
UnknownDietary Alteration of the Gut Microbiome and Its Impact on Weight and Fat Mass: A Systematic Review and Meta-Analysis.
Not available
S-EPMC5867888 | biostudies-literature
UnknownThe Use of Smartphone Keystroke Dynamics to Passively Monitor Upper Limb and Cognitive Function in Multiple Sclerosis: Longitudinal Analysis.
Not available
S-EPMC9679948 | biostudies-literature
UnknownNon-pharmacological interventions for sleep promotion in hospitalized children.
Not available
S-EPMC9199068 | biostudies-literature
UnknownReal-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis.
Not available
S-EPMC8358561 | biostudies-literature
UnknownMastocytosis presenting with mast cell-mediator release-associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features.
Not available
S-EPMC8967266 | biostudies-literature
UnknownSmartphone-derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis.
Not available
S-EPMC9299491 | biostudies-literature
UnknownEfficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
Not available
S-EPMC9647833 | biostudies-literature
UnknownEfficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.
Not available
S-EPMC9343245 | biostudies-literature
UnknownP1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
Not available
S-EPMC9429350 | biostudies-literature
UnknownP1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
Not available
S-EPMC9429120 | biostudies-literature
Sort   by:  
 Page size